# COLGALT1

## Overview
The COLGALT1 gene encodes the enzyme collagen beta(1-O)galactosyltransferase 1, a crucial component in the post-translational modification of collagen. This enzyme, categorized as a glycosyltransferase, is responsible for the galactosylation of hydroxylysine residues in collagen, a modification essential for the stability and function of collagen fibers. Operating within the endoplasmic reticulum, the enzyme facilitates the transfer of galactose to collagen polypeptides, which is vital for the structural integrity of various tissues, including bones, cartilage, and skin (Hennet2019Collagen; De2024Molecular). The enzyme's activity is dependent on metal ions, specifically Mn²⁺, and it plays a significant role in the biosynthesis and secretion of several collagen types, such as I, IV, and VI (Geister2019Loss; De2024Molecular). Mutations in COLGALT1 have been linked to various pathological conditions, including cerebral small vessel disease and certain cancers, highlighting its importance in both normal physiology and disease states (Liu2022COLGALT1; Miyatake2018Biallelic).

## Structure
The human gene COLGALT1 encodes the enzyme GLT25D1/COLGALT1, which is involved in the post-translational modification of collagen. The protein is characterized by an elongated head-to-head homodimeric assembly, with each monomer containing two Rossman fold-type domains, GT1 and GT2, separated by a 25-amino acid linker (De2024Molecular). The GT1 domain is primarily structural, essential for the correct quaternary structure assembly, while the GT2 domain serves as the functional catalytic site, containing a critical Glu-Asp-Asp motif for metal ion binding (De2024Molecular).

The enzyme binds Mn²⁺ cofactors and UDP-α-galactose donor substrates, with the GT2 domain identified as the active site for catalysis (De2024Molecular). The dimeric interface involves 22 hydrogen bonds and 5 salt bridges, contributing to a buried surface area of 1250 Å² (De2024Molecular). Although dimerization is not essential for enzymatic activity, it may play a role in substrate recognition and processing (De2024Molecular).

The protein is anchored to the endoplasmic reticulum via a C-terminal Arg-Asp-Glu-Leu (RDEL) sequence, ensuring its localization for collagen modification (De2024Molecular). The enzyme's structure and function are stabilized by interactions with metal ions and donor substrates, which are crucial for maintaining its conformation and activity (De2024Molecular).

## Function
The human gene COLGALT1 encodes a collagen glycosyltransferase enzyme that plays a crucial role in the post-translational modification of collagen. This enzyme is responsible for the galactosylation of hydroxylysine residues in collagen, a process essential for the stability and function of collagen supramolecular assemblies. The enzyme operates in the endoplasmic reticulum, where it transfers galactose to hydroxylysine residues on collagen polypeptides before the formation of the triple helix structure (Hennet2019Collagen; De2024Molecular). This modification is critical for maintaining the structural integrity of tissues such as bones, cartilage, tendons, and dermis (De2024Molecular).

COLGALT1 is involved in the glycosylation of several types of collagen, including collagens I, IV, and VI, which is crucial for their stability and proper secretion (Geister2019Loss). The presence of galactose on hydroxylysine has been shown to decrease interactions with certain integrins and cell surface proteins, potentially modulating cell adhesion and spreading on basement membranes (Hennet2019Collagen). In healthy cells, COLGALT1 ensures the proper modification and secretion of type IV collagen, maintaining the structural integrity of cerebral vessels (Miyatake2018Biallelic). The enzyme's activity is metal ion-dependent, requiring Mn2+ for its function, and it binds UDP-α-galactose donor substrates (De2024Molecular).

## Clinical Significance
Mutations in the COLGALT1 gene are associated with several significant health conditions. Biallelic variants in COLGALT1 have been linked to cerebral small vessel disease, a condition characterized by neurological symptoms such as hypotonia, epileptic seizures, and spastic quadriplegia. Brain imaging of affected individuals often reveals calcification, porencephaly, and leukoencephalopathy. These mutations, such as p.Leu151Arg and p.Ala154Pro, destabilize the ColGalT1 protein, impairing its enzymatic activity and leading to cerebral small vessel abnormalities (Miyatake2018Biallelic).

In musculoskeletal systems, mutations in COLGALT1 disrupt collagen post-translational modification, particularly affecting collagen types IV and VI. This disruption can lead to musculoskeletal defects, as observed in animal models, and is hypothesized to contribute to human connective tissue disorders (Geister2019Loss).

Altered expression of COLGALT1 is also implicated in cancer, particularly in kidney renal clear cell carcinoma (KIRC). High expression levels of COLGALT1 in KIRC are associated with advanced malignancies and poor prognosis. The gene's expression correlates with immune features and may contribute to tumor immune escape mechanisms, affecting T cell dysfunction and exclusion (Liu2022COLGALT1; Han2020COLGALT1).

## Interactions
COLGALT1, also known as collagen beta(1-O)galactosyltransferase 1, is involved in the post-translational modification of collagen, specifically in the glycosylation of hydroxylysine residues. This enzyme operates in the endoplasmic reticulum and is part of a family of galactosyltransferases that work alongside lysyl hydroxylases (LH/PLOD) to modify collagen lysine side chains. The co-localization of COLGALT1 with LH/PLOD enzymes suggests potential interactions between these enzyme systems during collagen biosynthesis (De2024Molecular).

In the context of kidney renal clear cell carcinoma (KIRC), COLGALT1 expression is associated with immune cell infiltration, including CD4+ T cells, B cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells. It is also linked to immune checkpoint genes such as BTLA, CD200, CD244, CD274, CD276, CD28, and CD80, indicating interactions within the tumor microenvironment (Liu2022COLGALT1).

Mutations in COLGALT1, such as p.Leu151Arg and p.Ala154Pro, have been shown to destabilize protein folding and impair enzymatic activity, affecting the post-translational modification of type IV collagen. This impairment leads to disrupted collagen secretion and contributes to vessel fragility, highlighting the importance of COLGALT1 in collagen biosynthesis and its interactions with collagen molecules (Miyatake2018Biallelic).


## References


[1. (Hennet2019Collagen) Thierry Hennet. Collagen glycosylation. Current Opinion in Structural Biology, 56:131–138, June 2019. URL: http://dx.doi.org/10.1016/j.sbi.2019.01.015, doi:10.1016/j.sbi.2019.01.015. This article has 98 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.sbi.2019.01.015)

[2. (Geister2019Loss) Krista A. Geister, Alberto Jose Lopez-Jimenez, Scott Houghtaling, Tzu-Hua Ho, Roberto Vanacore, and David R. Beier. Loss of function of colgalt1 disrupts collagen post-translational modification and causes musculoskeletal defects. Disease Models &amp; Mechanisms, June 2019. URL: http://dx.doi.org/10.1242/dmm.037176, doi:10.1242/dmm.037176. This article has 23 citations.](https://doi.org/10.1242/dmm.037176)

[3. (Miyatake2018Biallelic) Satoko Miyatake, Sacha Schneeberger, Norihisa Koyama, Kenji Yokochi, Kayo Ohmura, Masaaki Shiina, Harushi Mori, Eriko Koshimizu, Eri Imagawa, Yuri Uchiyama, Satomi Mitsuhashi, Martin C. Frith, Atsushi Fujita, Mai Satoh, Masataka Taguri, Yasuko Tomono, Keita Takahashi, Hiroshi Doi, Hideyuki Takeuchi, Mitsuko Nakashima, Takeshi Mizuguchi, Atsushi Takata, Noriko Miyake, Hirotomo Saitsu, Fumiaki Tanaka, Kazuhiro Ogata, Thierry Hennet, and Naomichi Matsumoto. Biallelic colgalt1 variants are associated with cerebral small vessel disease. Annals of Neurology, 84(6):843–853, November 2018. URL: http://dx.doi.org/10.1002/ana.25367, doi:10.1002/ana.25367. This article has 39 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.25367)

4. (Han2020COLGALT1) COLGALT1 is a Prognostic Biomarker in Clear Renal Cell Carcinoma Correlated with Immune Infiltrates: A Study Based on TCGA Data. This article has 1 citations.

5. (De2024Molecular) Molecular Structure and Enzymatic Mechanism of the Human Collagen Hydroxylysine Galactosyltransferase GLT25D1/COLGALT1. This article has 0 citations.

[6. (Liu2022COLGALT1) Shiwei Liu, Yang Yu, Yi Wang, Bingye Zhu, and Bangmin Han. Colgalt1 is a potential biomarker for predicting prognosis and immune responses for kidney renal clear cell carcinoma and its mechanisms of cerna networks. European Journal of Medical Research, July 2022. URL: http://dx.doi.org/10.1186/s40001-022-00745-5, doi:10.1186/s40001-022-00745-5. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s40001-022-00745-5)